ClinicalTrials.gg
CompletedNCT05757596Updated Mar 20, 2025

Study of VSA001 Injection in Chinese Healthy Adult Volunteers

A Phase 1 interventional study of VSA001 injection and Placebo in Healthy Adult Volunteers, sponsored by Visirna Therapeutics HK Limited. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Visirna Therapeutics HK Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase 1, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effects of a single dose of VSA001 injection in Chinese healthy adult volunteers. Eligible enrolled participants will initially receive VSA001 injection at the assigned dose level.

02

Conditions studied

  • Healthy Adult Volunteers
03

In context

Lead sponsor

Visirna Therapeutics HK Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects voluntarily participate in this study who are able to read, understand, and sign the ICF before participation; and have a full understanding of the content, process and possible adverse reactions of the study and are able to complete the study in accordance with the requirements of the protocol.
  2. Healthy male and female subjects aged between 18 and 55 years (both inclusive) at the time of .
  3. (BMI) = weight (kg)/height (m)2, within the range of 19.0-30.0 kg/m2 (both inclusive), and body weight no less than 50 kg.
  4. In good general health and without abnormalities as judged by the investigator, based on medical history, physical examination, vital signs, 12-lead , and laboratory results.
  5. Negative serum pregnancy test within 72 h prior to initiation of study treatment in all premenopausal females and females who have been amenorrheic for less than 12 months. (Serum pregnancy test is not required for females who have undergone surgical sterilization, such as hysterectomy and/or bilateral oophorectomy, or those who have not experienced menses for 12 consecutive months and are judged to be based on factors such as age and castration therapy).
  6. Subjects and their partners must agree to use adequate methods prior to initiation of study treatment, during the study, and for at least 3 months after discontinuation of study treatment.
  7. Fasting serum TGs >80 mg/dL (>0.903 mmol/L) at screening.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of significant or diseases/abnormality, including but not limited to cardiac/cardiovascular, respiratory, endocrine, gastrointestinal, renal, hepatic, gallbladder, dermatological, hematological, immunological, neurologic, or psychiatric diseases/abnormality, or the disease that, in the judgement of the investigator, present a safety concern or affects the pharmacokinetic evaluation.
  2. A family history of congenital long syndrome, Brugada syndrome or unexplained sudden cardiac death.
  3. Subjects who are with acute exacerbation of any significant acute or chronic disease as judged by the investigator.
  4. and ALT >2× (ULN) , or total >ULN at screening.
  5. Serum creatinine estimated \< 60 ml/min/1.73 m2 per MDRD formula.
  6. Cardiac troponin (troponin I) above ULN at Screening.
  7. Fasting serum TGs >300 mg/dL (>3.38 mmol/L) at screening.
  8. Presence of other conditions or treatments that may affect the study results and interfere with the subject's participation in the study as assessed by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    VSA001 injection

    A single dose of active drug (VSA001, low or high dose) will be administered by subcutaneous injection on Day 1.

    Drug: VSA001 injection

  • Placebo comparator
    Placebo

    The placebo is normal saline (0.9%) administered subcutaneously; volume matched to the corresponding VSA001 dose volume.

    Drug: Placebo

Interventions

  • DrugVSA001 injection

    The active drug is VSA001 injection. The active pharmaceutical ingredient (API) contained in VSA001 is a synthetic, double-stranded, hepatocyte targeted NAG-conjugated RNAi.

  • DrugPlacebo

    0.9% Saline, volume matched

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs), and the relationship with VSA-01001. Clinically significant abnormalities in laboratory tests, vital signs, physical examination, 12-lead electrocardiograms (ECG).

    Time frame: 85 days

Secondary outcomes

  1. Pharmacokinetics parameter: Cmax

    Maximum plasma concentration (Cmax)

    Time frame: 48 hours

  2. Pharmacokinetics parameter: Tmax

    Time to maximum plasma concentration (Tmax)

    Time frame: 48 hours

  3. Pharmacokinetics parameter: AUC0-t

    Area under the plasma concentration-time curve from the time 0 to the last quantifiable time point (AUC0-t).

    Time frame: 48 hours

  4. Pharmacokinetics parameter: t1/2

    Half-life (t1/2).

    Time frame: 48 hours

  5. Pharmacokinetics parameter: CL/F

    Apparent clearance (CL/F).

    Time frame: 48 hours

  6. Pharmacokinetics parameter: Vz/F

    Apparent volume of distribution (Vz/F).

    Time frame: 48 hours

  7. Pharmacodynamic (PD) parameters

    Change from baseline over time in fasting serum APOC3 and triglycerides (TGs).

    Time frame: 85 days

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Sep 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Mar 7, 2023
StartActual
May 17, 2023
Primary completionActual
Sep 25, 2023
CompletionActual
Dec 31, 2023
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05757596
Lead sponsor
Visirna Therapeutics HK Limited
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
May 17, 2023
Primary completion
Sep 25, 2023
Completion
Dec 31, 2023
Last update
Mar 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion